|
시장보고서
상품코드
1983350
페메트렉시드 시장 : 투여량별, 판매 채널별, 지역별Pemetrexed Market, By Strength (100 mg ,500 mg), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) |
||||||
페메트렉시드 시장은 2026년에 24억 9,420만 달러로 추정되고 있으며, 2033년까지 29억 760만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 2.2%로 성장할 것으로 전망되고 있습니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준연도 | 2025년 | 시장 규모(2026년) | 24억 9,420만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간의 CAGR(2026-2033년) | 2.20% | 예측 금액(2033년) | 29억 760만 달러 |
페메트렉세드는 흉막중피종 및 비소세포폐암 치료에 사용되는 화학요법제입니다. 페메트렉시드는 일라이 릴리의 특허 의약품으로 '아리무타'라는 브랜드로 판매되고 있습니다. 2004년, 아리무타(페메트렉세이드 주사액)는 미국 FDA(식품의약국)로부터 악성 흉막중피종 환자의 초기 치료제로 시스플라틴과의 병용요법으로 승인받았습니다. 백금 기반 1차 항암화학요법 4주기 치료 후에도 병이 진행되지 않은 국소 진행성 또는 전이성 비편평상피(비소세포) 폐암(NSCLC) 환자의 유지요법에서 단독요법으로 사용됩니다. 또한 화학요법 후 재발 및 전이성 비편평상피(비소세포) 폐암(NSCLC) 환자의 치료에 단독요법으로도 사용됩니다.
시장 역학
주요 지역에서 페메트렉세드의 제네릭 의약품 출시로 인해 페메트렉세드의 접근성이 향상될 것으로 예상되며, 이는 예측 기간 중 글로벌 페메트렉세드 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 2018년 7월 STADA Arzneimittel AG의 자회사인 국제 제약사 STADAPHARM GmbH는 유럽에서 알리무타(Alimta)의 제네릭 의약품인 '페메트렉세드 스타다(Pemetrexed STADA)를 출시하였다. 이 약은 국소 진행성, 전이성 및 비소세포폐암 치료에 사용되며, 릴리(Lilly)의 제품인 아리무타의 제네릭 의약품입니다. 이번 출시는 제약 분야에서의 사업 확장에 기여한 것으로 평가받고 있습니다.
비소세포폐암과 흉막중피종의 높은 유병률은 페메트렉시드에 대한 수요를 증가시켜 예측 기간 중 글로벌 페메트렉시드 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 종양학 단체인 미국임상종양학회(ASCO)가 발표한 자료에 따르면 2018년 1월 기준 미국에서는 약 23만 4,030명의 성인(남성 12만 1,680명, 여성 11만 2,350명)이 폐암 진단을 받았으며, 이 중 비소세포폐암이 가장 흔한 폐암 유형으로 전체 폐암 진단의 80-85%를 차지하고 있습니다. 전체 폐암 진단의 80-85%를 차지하고 있습니다.
또한 시장의 주요 기업은 매출 확대와 높은 매출 창출을 위해 페메트렉세드 약물의 적응증 확대에 주력하고 있습니다. 예를 들어 2018년 6월 미국 식품의약국(FDA)으로부터 ALIMTA(페메트렉시드 주사제)를 카보플라틴 및 KEYTRUDA(펨브롤리주맙)와 병용하여 PD-L1 발현율에 관계없이 전이성 비편평상피성 비소세포폐암 환자의 1차 치료제로 승인받았습니다. 전이성 비편평상피성 비소세포폐암(NSCLC) 환자의 1차 치료에 대한 적응증을 획득했습니다.
이 보고서의 주요 특징
- 세계의 페메트렉세드(Pemetrexed) 시장에 대해 조사 분석했으며, 2025년을 기준연도로 하여 예측 기간(2026-2033년) 시장 규모와 연평균 성장률(CAGR)을 조사 분석하여 전해드립니다.
- 또한 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요 인사이트를 제공합니다.
- 글로벌 페메트렉시드 시장의 주요 기업 개요을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등의 매개 변수를 기반으로 작성되었습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '글로벌 페메트렉시드 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 글로벌 페메트렉시드 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 페메트렉시드 시장 : 투여량별(2026-2033년)
제5장 세계의 페메트렉시드 시장 : 유통 채널별(2026-2033년)
제6장 세계의 페메트렉시드 시장 : 지역별(2026-2033년)
제7장 경쟁 구도
제8장 섹션
KSA 26.04.24Pemetrexed Market is estimated to be valued at USD 2,494.2 Mn in 2026 and is expected to reach USD 2,907.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 2.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2,494.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 2.20% | 2033 Value Projection: | USD 2,907.6 Mn |
Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by US FDA (Food and Drug Administration) in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. As a single agent for the maintenance treatment of patients with locally advanced or metastatic non squamous (non-small cell lung cancer) NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. It is a single agent for the treatment of patients with recurrent, metastatic non-squamous (non-small cell lung cancer) NSCLC after prior chemotherapy.
Market Dynamics
Launch of generic version of pemetrexed in key region is expected to increase affordability of pemetrexed, which in turn is expected to drive global pemetrexed market growth over the forecast period. For instance, in July 2018, STADAPHARM GmbH, an international pharmaceutical company the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe. The drug is used for treating locally advanced, metastasized and non-small cell lung cancer and is a generic of the product Alimta by Lilly. The launch helped the company in further expansion in pharmaceutical sector.
High prevalence of non-small cell lung cancer and pleural mesothelioma is expected to rise the demand for pemetrexed drive global pemetrexed market growth over the forecast period. For instance, according to the data published by American Society of Clinical Oncology, an oncology organization, in January 2018, in the U.S. around 234,030 adults (121,680 men and 112,350 women) were diagnosed with lung cancer among which non-small cell lung cancer is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer diagnose.
Furthermore, key players in the market are dedicated to expand the indication of its pemetrexed drugs in order to increase its sale and generate high revenues. For instance, in June 2018, Eli Lilly and Company, a U.S.-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for a new indication for ALIMTA (pemetrexed for injection) in combination with carboplatin and KEYTRUDA (pembrolizumab) for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.
Key features of the study
- This report provides an in-depth analysis of the global pemetrexed market, market size (USD Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026 - 2033, considering 2025 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global pemetrexed market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include, Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc, Fresenius Kabi USA, Teva Pharmaceuticals USA, Inc, Biocon, Pfizer Inc., Apotex Inc, Dr. Reddy's Laboratories Ltd, Cadila Pharmaceuticals., Accord Healthcare, Accure Labs Pvt. Ltd, Shanghai Henlius Biotech, Inc., Janssen Global Services, LLC, and Checkpoint Therapeutics, Inc..
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global pemetrexed market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global pemetrexed market.
Market Segmentation
- Strength Insights (Revenue, USD Mn, 2026 - 2033)
- 100mg
- 500mg
- Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Eli Lilly and Company
- Stada Arzneimittel AG
- Eagle Pharmaceuticals, Inc
- Fresenius Kabi USA
- Teva Pharmaceuticals USA, Inc
- Biocon
- Pfizer Inc.
- Apotex Inc
- Reddy's Laboratories Ltd
- Cadila Pharmaceuticals.
- Accord Healthcare
- Accure Labs Pvt. Ltd
- Shanghai Henlius Biotech, Inc.
- Janssen Global Services, LLC
- Checkpoint Therapeutics, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Strength
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Novel Product Launch/Approval
- Merger-Acquisition Scenario
- PEST Analysis
- Regulatory Scenario
- Reimbursement Scenario
- Epidemiology
4. Global Pemetrexed Market, By Strength, 2026-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- 100mg
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- 500mg
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
5. Global Pemetrexed Market, By Distribution Channel, 2026-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Online Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Pemetrexed Market, By Region, 2026-2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profiles
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Stada Arzneimittel AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Eagle Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Fresenius Kabi USA
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Teva Pharmaceuticals USA, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Biocon
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Apotex Inc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Reddy's Laboratories Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cadila Pharmaceuticals.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Accord Healthcare
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Accure Labs Pvt. Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Shanghai Henlius Biotech, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Janssen Global Services, LLC,
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Checkpoint Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
- Eli Lilly and Company
8. Section
- Research Methodology
- About Us
(주말 및 공휴일 제외)
